BRPI0818170A2 - 5-cianotienopiridinas para o tratamento de tumores. - Google Patents

5-cianotienopiridinas para o tratamento de tumores.

Info

Publication number
BRPI0818170A2
BRPI0818170A2 BRPI0818170A BRPI0818170A BRPI0818170A2 BR PI0818170 A2 BRPI0818170 A2 BR PI0818170A2 BR PI0818170 A BRPI0818170 A BR PI0818170A BR PI0818170 A BRPI0818170 A BR PI0818170A BR PI0818170 A2 BRPI0818170 A2 BR PI0818170A2
Authority
BR
Brazil
Prior art keywords
cyanothienopyridines
tumors
treatment
Prior art date
Application number
BRPI0818170A
Other languages
English (en)
Inventor
Amendt Christiane
Musil Djordje
Hoelzemann Guenter
Greiner Hartmut
Hillertz Per
Graedler Ulrich
Original Assignee
Merck Patent Ges Mit Berschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Berschränkter Haftung filed Critical Merck Patent Ges Mit Berschränkter Haftung
Publication of BRPI0818170A2 publication Critical patent/BRPI0818170A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0818170A 2007-10-16 2008-09-19 5-cianotienopiridinas para o tratamento de tumores. BRPI0818170A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007049451A DE102007049451A1 (de) 2007-10-16 2007-10-16 5-Cyano-thienopyridine
PCT/EP2008/007888 WO2009049743A1 (de) 2007-10-16 2008-09-19 5-cyano-thienopyridine zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
BRPI0818170A2 true BRPI0818170A2 (pt) 2017-05-16

Family

ID=40262956

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818170A BRPI0818170A2 (pt) 2007-10-16 2008-09-19 5-cianotienopiridinas para o tratamento de tumores.

Country Status (16)

Country Link
US (1) US8202882B2 (pt)
EP (1) EP2197886B1 (pt)
JP (1) JP5480811B2 (pt)
KR (1) KR20100076026A (pt)
CN (1) CN101827851A (pt)
AR (1) AR068872A1 (pt)
AU (1) AU2008314245B2 (pt)
BR (1) BRPI0818170A2 (pt)
CA (1) CA2702551A1 (pt)
DE (1) DE102007049451A1 (pt)
EA (1) EA201000618A1 (pt)
ES (1) ES2401936T3 (pt)
IL (1) IL205137A0 (pt)
MX (1) MX2010004017A (pt)
WO (1) WO2009049743A1 (pt)
ZA (1) ZA201003425B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7904970B2 (en) 2009-02-20 2011-03-15 J-Brem, LLC Headwear with features for holding eyeglasses
BR112012018954A2 (pt) 2010-02-05 2016-04-12 Merck Patent Gmbh derivados de hetaril-[1,8]naftiridina
SG183233A1 (en) 2010-02-22 2012-09-27 Merck Patent Gmbh Hetarylaminonaphthyridines
US9499538B2 (en) * 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
WO2014111037A1 (zh) * 2013-01-18 2014-07-24 上海昀怡健康管理咨询有限公司 五元并六元杂环化合物、其制备方法、药物组合物和应用
AU2014342811B2 (en) * 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CN107921025A (zh) 2015-03-08 2018-04-17 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
DE102005009440A1 (de) * 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
DE102005024245A1 (de) 2005-05-27 2006-11-30 Merck Patent Gmbh Thienopyridine

Also Published As

Publication number Publication date
KR20100076026A (ko) 2010-07-05
US8202882B2 (en) 2012-06-19
DE102007049451A1 (de) 2009-04-23
ES2401936T3 (es) 2013-04-25
MX2010004017A (es) 2010-04-27
EP2197886A1 (de) 2010-06-23
JP2011500610A (ja) 2011-01-06
IL205137A0 (en) 2010-11-30
CA2702551A1 (en) 2009-04-23
JP5480811B2 (ja) 2014-04-23
CN101827851A (zh) 2010-09-08
EA201000618A1 (ru) 2011-04-29
EP2197886B1 (de) 2012-12-26
WO2009049743A1 (de) 2009-04-23
AR068872A1 (es) 2009-12-09
AU2008314245B2 (en) 2013-07-18
AU2008314245A1 (en) 2009-04-23
US20100234369A1 (en) 2010-09-16
ZA201003425B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0814542A2 (pt) Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0813670A2 (pt) Compostos para tratamento
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
DK2121139T3 (da) Formulations for cancer treatment
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0922884A2 (pt) compostos para tratamento de câncer
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]